G. Villanova

发表

Biochemical and Pharmacological Properties of SR 49059 , a New , Potent , Nonpeptide Antagonist of Rat and Human Vasopressin Via Receptors

Ala, C. S. Gal, S., 2022 .

Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

C. S. Gal, J. Maffrand, J. Wagnon, 1993, The Journal of clinical investigation.

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial

H. Sommer, M. Untch, P. Kellokumpu-Lehtinen, 2006, British Journal of Cancer.

Final Results of the Randomized Phase II NorCap‐CA223 Trial Comparing First‐Line All‐Oral Versus Taxane‐Based Chemotherapy for HER2‐Negative Metastatic Breast Cancer

A. Barnadas, A. Chan, Michiel Botha, 2017, Clinical breast cancer.

Biochemical and Pharmacological Properties of SR 49059 , a New , Potent , Nonpeptide Antagonist of Rat and HumanVasopressin Via Receptors

G. Guillon, D. Nisato, C. Barberis, 2013 .

Effects of SR 49059, a non‐peptide antagonist of vasopressin V1a receptors, on vasopressin‐induced coronary vasoconstriction in conscious rabbits

C. S. Gal, G. Fur, J. Maffrand, 1995, Fundamental & clinical pharmacology.

Abstract OT3-02-04: Randomised phase II study evaluating, as first-line chemotherapy, single-agent oral vinorelbine administered with two different schedules in patients with hormone receptor positive, HER2-negative advanced breast cancer (TempoBreast-1 trial)

F. Cardoso, E. Starosławska, E. Petru, 2016 .

Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial).

M. Aapro, R. Freitas-Junior, S. Morales, 2019, Breast.

Modification of two models of Arthus reaction in the rat by various drugs.

G. Villanova, M. Bru, J. Tarayre, 1982, Arzneimittel-Forschung.

Pharmacological study of cantharidin-induced ear inflammation in mice.

M. Aliaga, G. Villanova, J. Tarayre, 1984, Journal of pharmacological methods.

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.

M. Espié, V. Ganju, P. Conte, 2013, Anticancer research.

403PPHASE II STUDY EVALUATING ORAL VINORELBINE AS A SINGLE-AGENT AS FIRST-LINE CHEMOTHERAPY FOR METASTATIC BREAST CANCER PATIENTS WITH BONE METASTASES (NORBREAST-228 TRIAL): FIRST EFFICACY RESULTS.

E. Espinosa, M. Benasso, M. Błasińska-Morawiec, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial

M. Espié, P. Conte, P. Conte, 2009, British Journal of Cancer.

2130 POSTER Updated analysis of an international phase II study evaluating an all-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer (MBC)

M. Espié, P. Conte, A. Chan, 2007 .

Lotifazole (F 1686), a non-steroidal anti-inflammatory agent with an unusual pharmacological spectrum

M. Aliaga, G. Villanova, M. Bru, 2005, Agents and Actions.

Single‐Agent Oral Vinorelbine as First‐Line Chemotherapy for Endocrine‐Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST‐228 Phase II Study

E. Espinosa, M. Błasińska-Morawiec, G. Steger, 2017, Clinical breast cancer.

Pharmacological comparison of the immune and non-immune inflammations induced by picryl chloride and oxazolone in mice.

M. Aliaga, G. Villanova, M. Bru, 1984, Archives internationales de pharmacodynamie et de therapie.

Cutaneously applied erythromycin base reduces various types of inflammatory reactions in mouse ear.

J. Couzinier, M. Aliaga, G. Villanova, 1987, International journal of tissue reactions.

Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study

S. Morales, M. Cazzaniga, G. Villanova, 2024, Breast.

All-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): latest results of a multicenter, international phase II trial with a median follow-up of 37.7 months.

M. Espié, P. Conte, N. Tubiana-Mathieu, 2009 .